Companies in #Type 1 Diabetes

Kriya Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing AAV-based gene therapies for common chronic diseases of high unmet need, including Type 1 diabetes, obesity, oncology, and rare diseases. Unlike most AAV gene therapy companies that focus on rare diseases with small patient populations, Kriya's strategic differentiation is targeting chronic conditions with much larger patient populations. Kriya operates its own in-house, large-scale GMP manufacturing facilities for gene therapy at its Research Triangle Park (Durham, North Carolina) headquarters — a notable strategic departure from the typical gene therapy CDMO-out-source model. The company was founded in 2019 by Shankar Ramaswamy, M.D. (former senior partner at McKinsey and former CEO of Axovant) and has raised over $600M in venture funding. Kriya was selected in June 2026 for the FDA PreCheck Pilot Program for its Durham, NC manufacturing facility.

Modular Medical, Inc. is a medical device company developing a next-generation, low-cost insulin pump technology intended to expand access to insulin pump therapy for people with diabetes. The company is pursuing U.S. FDA clearance for its modular pump platform, targeting the type 1 and insulin-requiring type 2 diabetes markets with a simplified, affordable patch-pump design. Following the March 31, 2026 1-for-30 reverse stock split (reducing outstanding shares from 139.8M to approximately 4.66M to address Nasdaq's $1.00 minimum bid price requirement), the company continues to trade on Nasdaq under the MODD symbol. Modular Medical's pipeline targets the broader insulin-delivery market currently served by incumbents including Tandem Diabetes Care, Insulet, and Medtronic Diabetes.

Vertex Pharmaceuticals is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. Vertex is the leading developer of cystic fibrosis therapies (Trikafta/Kaftrio franchise), brought the first FDA-approved CRISPR-based therapy to market (Casgevy, with CRISPR Therapeutics), and has a late-stage pipeline in acute pain, sickle cell disease, beta thalassemia, and Duchenne muscular dystrophy.